<DOC>
	<DOCNO>NCT02822794</DOCNO>
	<brief_summary>The primary objective study evaluate antiviral efficacy , safety , tolerability therapy sofosbuvir/velpatasvir ( SOF/VEL ) fixed-dose combination ( FDC ) ribavirin ( RBV ) participants chronic hepatitis C virus ( HCV ) previously fail direct-acting antiviral ( DAA ) -containing regimen .</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed-Dose Combination Ribavirin 12 24 Weeks Participants With Chronic Genotype 1 2 Hepatitis C Virus Infection Who Have Previously Failed Direct-Acting Antiviral-Containing Regimen</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Genotype 1 2 HCV infection Chronic HCV infection ( â‰¥ 6 month prior screen ) document prior medical history liver biopsy Previously treat DAAcontaining regimen least 4 week duration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>